New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2014
18:09 EDTMDTMedtronic's CoreValve shows superior results to surgical valve replacement
Medtronic announced that the CoreValve System showed results superior to surgical aortic valve replacement, SAVR, at one year in the High Risk Study of its CoreValve U.S. Pivotal Trial, which evaluated patients with severe aortic stenosis who are considered high risk for surgery. The data were presented at a late-breaking clinical trial session at the 63rd Annual Scientific Session of the American College of Cardiology, ACC, and simultaneously published in The New England Journal of Medicine. The CoreValve System was approved by the U.S. Food and Drug Administration, FDA, in January 2014 for patients considered extreme risk for surgery; the device is not currently approved in the U.S. for use with patients at high risk. The head-to-head study met its primary endpoint with a low one year, all-cause mortality rate of only 14.2% in patients receiving the CoreValve System, compared to 19.1% in patients receiving SAVR at one year. The CoreValve High Risk Study is the first prospective, randomized study to show any transcatheter aortic valve to be superior to surgery. "The extremely low mortality rates in both arms of the trial confirm that our heart teams were outstanding, particularly considering they had no prior experience with transcatheter aortic valve therapy, said David H. Adams, M.D., chair of the Department of Cardiothoracic Surgery at the Mount Sinai Hospital, New York City, national co-principal investigator of the CoreValve U. S. Pivotal Trial and presenter of the data at ACC. "Our key finding that TAVR with CoreValve was associated with a significantly higher rate of survival at one year in patients at increased risk has significant and broad implications."
News For MDT From The Last 14 Days
Check below for free stories on MDT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
08:16 EDTMDTDeutsche Bank analysts hold an analyst/industry conference call
Subscribe for More Information
July 18, 2014
12:51 EDTMDTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 16, 2014
10:36 EDTMDTTreasury calls on Congress to halt inversion deals
Subscribe for More Information
07:59 EDTMDTTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:18 EDTMDTScoliosis Research Society to hold annual meeting
Subscribe for More Information
July 14, 2014
07:12 EDTMDTCovidien downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
July 10, 2014
08:02 EDTMDTCryoLife appoints Pat Mackin as President and CEO effective September 2
Mackin is expected to be appointed to the company's board after his employment begins. Steven Anderson will continue to serve CryoLife (CRY) as its President and Chief Executive Officer until Mackin's employment begins and then continue as its Executive Chairman. Mackin joins CryoLife from Medtronic (MDT), where he most recently served as President of Cardiac Rhythm Disease Management.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use